The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Hun Ju Lee, MD, discusses the potential utility of ibrutinib in combination with cirmtuzumab in mantle cell lymphoma.

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.

February 15, 2021 - Zanidatamab demonstrated promising antitumor activity with favorable tolerability in patients with HER2-expressing gastroesophageal adenocarcinoma that has progressed following previous therapies, including HER2-targeted agents.

February 2, 2021 - Emil J. Freireich, MD, DSc, a founding father of modern clinical cancer research and the 2015 Giants of Cancer Care award winner for Lymphoid Neoplasms, has died at age 93.

Matthew T. Campbell, MD, MS, discusses the importance of utilizing a multidisciplinary treatment approach in renal cell carcinoma.

Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.

Ecaterina Ileana Dumbrava, MD, discusses the mechanism of action of BDC-1001 in advanced HER2-expressing breast cancer.

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer.

David S. Hong, MD, discusses the potential clinical implications of the phase 1 SURPASS trial in gastric/gastroesophageal junction cancer.

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

A gene expression signature based on tumor cell lineage/state compositions can predict survival in patients with peritoneal carcinomatosis.

Debu Tripathy, MD, discusses strategies that can be used to overcome ESR1 mutations in estrogen receptor–positive breast cancer.

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib and rituximab in elderly patients with previously untreated mantle cell lymphoma.

Hun Ju Lee, MD, discusses responses to cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma.

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.

Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation.

Hussein A. Tawbi, MD, PhD, discusses future research efforts in melanoma.

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.